Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Wondrak GT.

Antioxid Redox Signal. 2009 Dec;11(12):3013-69. doi: 10.1089/ARS.2009.2541. Review.

2.

Experimental therapeutics: targeting the redox Achilles heel of cancer.

Cabello CM, Bair WB 3rd, Wondrak GT.

Curr Opin Investig Drugs. 2007 Dec;8(12):1022-37. Review.

PMID:
18058573
3.

Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (review).

Möhler H, Pfirrmann RW, Frei K.

Int J Oncol. 2014 Oct;45(4):1329-36. doi: 10.3892/ijo.2014.2566. Epub 2014 Jul 28. Review.

4.

Redox-active and redox-silent compounds: synergistic therapeutics in cancer.

Tomasetti M, Santarelli L, Alleva R, Dong LF, Neuzil J.

Curr Med Chem. 2015;22(5):552-68.

PMID:
25245377
5.

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G.

Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Review.

PMID:
26983373
7.

Targeting tumor suppressor genes for cancer therapy.

Liu Y, Hu X, Han C, Wang L, Zhang X, He X, Lu X.

Bioessays. 2015 Dec;37(12):1277-86. doi: 10.1002/bies.201500093. Epub 2015 Oct 7. Review.

PMID:
26445307
8.

Redox platforms in cancer drug discovery and development.

Tew KD, Townsend DM.

Curr Opin Chem Biol. 2011 Feb;15(1):156-61. doi: 10.1016/j.cbpa.2010.10.016. Epub 2010 Nov 11. Review.

9.

Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.

Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, Gius D.

Drug Resist Updat. 2005 Oct;8(5):322-30. Epub 2005 Oct 17. Review.

PMID:
16230045
10.

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):513-20. Review.

PMID:
16890805
11.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
12.

Motexafin gadolinium: a novel redox active drug for cancer therapy.

Magda D, Miller RA.

Semin Cancer Biol. 2006 Dec;16(6):466-76. Epub 2006 Sep 26. Review.

PMID:
17112739
13.

The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy.

Biaglow JE, Miller RA.

Cancer Biol Ther. 2005 Jan;4(1):6-13. Epub 2004 Jan 8. Review.

PMID:
15684606
14.

The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Grek CL, Townsend DM, Tew KD.

Pharmacol Ther. 2011 Feb;129(2):172-84. doi: 10.1016/j.pharmthera.2010.09.008. Epub 2010 Oct 15. Review.

15.

Redox regulation of cancer metastasis: molecular signaling and therapeutic opportunities.

Yang W, Zou L, Huang C, Lei Y.

Drug Dev Res. 2014 Aug;75(5):331-41. doi: 10.1002/ddr.21216. Review.

PMID:
25160073
16.

Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Kuo MT.

Antioxid Redox Signal. 2009 Jan;11(1):99-133. doi: 10.1089/ars.2008.2095. Review.

17.

Synthetic lethality to overcome cancer drug resistance.

Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Brunetti AE, Calvert H, Paradiso A, Azzariti A.

Curr Med Chem. 2012;19(23):3858-73. Review.

PMID:
22788762
18.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
19.

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N.

Cancer Sci. 2003 Jan;94(1):15-21. Review.

20.

Selenium compounds as therapeutic agents in cancer.

Fernandes AP, Gandin V.

Biochim Biophys Acta. 2015 Aug;1850(8):1642-60. doi: 10.1016/j.bbagen.2014.10.008. Epub 2014 Oct 16. Review.

PMID:
25459512

Supplemental Content

Support Center